AI
RARE icon

Atom Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Atom Investors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Buy
+93,622
New +$2.11M 0.14% 251

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Atom Investors's RARE Position: Q1 2026 in Review

Atom Investors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 93,622 shares worth $1.96M. The stake represents 0.14% of the portfolio and ranks #251 among its holdings.

296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Atom Investors held 93,622 shares of Ultragenyx Pharmaceutical worth $1.96M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Atom Investors position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.14% of Atom Investors's portfolio in Q1 2026, its #251 holding.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.